Sustained Release of αO-Conotoxin GeXIVA[1,2] via Hydrogel Microneedle Patch for Chronic Neuropathic Pain Management
Marine Drugs · 2025
DOI: 10.3390/md23040161 ↗Kurz gefasst
Fachartikel in der Zeitschrift Marine Drugs, 2025. Verfasst von Rongyan He und 8 weiteren Autor:innen. Beteiligte Einrichtung: Guangxi Key Laboratory of Special Biomedicine, School of Medicine, Guangxi University, Nanning 530004, China. Hauptthemen laut MEDLINE: Neuralgia, Conotoxins, Analgesics, Chronic Pain. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Major Intergovernmental Joint Research Project of National Key R & D Program of China, Guangxi Natural Science Foundation, Major International Joint Research Project of National Natural Science Foundation of China.
Themen: Schmerzmanagement
Abstract (Originalsprache)
Chronic neuropathic pain severely impairs quality of life, with current therapies often causing adverse effects. Our research group identified αO-conotoxin GeXIVA[1,2] as a potent analgesic candidate derived from marine cone snails. However, its clinical application is limited by rapid clearance and complex administration. This study developed a sustained-release hydrogel microneedle patch encapsulating GeXIVA[1,2] to address these challenges. Optimized 4:3 (w/w) polyvinyl alcohol (PVA)–sucrose hydrogel formulation achieved 98.6% structural integrity and controlled swelling (ratio = 1.9 at 48 h). The microneedles demonstrated uniform conical morphology (height: 889 ± 49 µm, base: 381 ± 26 µm) enabling epidermal penetration. In spared nerve injury (SNI) models, a single microneedle patch application increased mechanical paw withdrawal thresholds from 0.056 g to 0.7269 g, maintaining efficacy for 3 days. Chronic constriction injury (CCI) models showed comparable pain relief. Notably, microneedle patch treatment improved locomotor function in SNI mice (total movement: 1518 cm vs. 1126 cm untreated). This hydrogel microneedle patch platform extends GeXIVA[1,2]’s analgesic duration from hours to days through sustained release, while resolving administration challenges through transdermal delivery, expanding the potential applications of GeXIVA[1,2], and demonstrating a promising strategy for the chronic neuropathic pain management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangxi Key Laboratory of Special Biomedicine, School of Medicine, Guangxi University, Nanning 530004, China.
- Key Laboratory of Tropical Biological Resources of Ministry of Education, Hainan University, Haikou 570228, China.
ORCID-Profile: Sulan Luo
Förderung
- Major Intergovernmental Joint Research Project of National Key R & D Program of China
- Guangxi Natural Science Foundation
- Major International Joint Research Project of National Natural Science Foundation of China
- National Natural Science Foundation of China
- "Dai Tu Yi Zhi" Project of Key R & D Program of Guangxi
- Key Project of Natural Science Foundation of Guangxi
- Major Intergovernmental Joint Research Project of National Key R & D Program of China
- “Dai Tu Yi Zhi” Project of Key R & D Program of Guangxi
Zitieren
APA
He, R., Li, M., Li, W., Li, W., Xiao, S., Cao, Q., Wang, H., Zhangsun, D., & Luo, S. (2025). Sustained Release of αO-Conotoxin GeXIVA[1,2] via Hydrogel Microneedle Patch for Chronic Neuropathic Pain Management. Marine Drugs. https://doi.org/10.3390/md23040161
Vancouver
He R, Li M, Li W, Li W, Xiao S, Cao Q, et al. Sustained Release of αO-Conotoxin GeXIVA[1,2] via Hydrogel Microneedle Patch for Chronic Neuropathic Pain Management. Marine Drugs. 2025. doi:10.3390/md23040161
BibTeX
@article{He2025,
author = {He, Rongyan and Li, Mingjuan and Li, Weitao and Li, Wenqi and Xiao, Shuting and Cao, Qiuyu and Wang, Huanbai and Zhangsun, Dongting and Luo, Sulan},
title = {Sustained Release of αO-Conotoxin GeXIVA[1,2] via Hydrogel Microneedle Patch for Chronic Neuropathic Pain Management},
journal = {Marine Drugs},
year = {2025},
doi = {10.3390/md23040161}
}
EUVIMED